Symbol="ARGX"
AssetType="Common Stock"
Name="argenx NV ADR"
Description="argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands."
CIK="1697862"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, BE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="30778882000"
EBITDA="-479285760"
PERatio="None"
PEGRatio="0"
BookValue="2.032"
DividendPerShare="0"
DividendYield="0"
EPS="-9.74"
RevenuePerShareTTM="0.463"
ProfitMargin="-0.8"
OperatingMarginTTM="-0.946"
ReturnOnAssetsTTM="-0.151"
ReturnOnEquityTTM="-0.265"
RevenueTTM="639411000"
GrossProfitTTM="-251786000"
DilutedEPSTTM="-9.74"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.3"
AnalystTargetPrice="545.45"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="78.22"
PriceToBookRatio="7.24"
EVToRevenue="72.3"
EVToEBITDA="-21.25"
Beta="0.429"
num_52WeekHigh="550.76"
num_52WeekLow="333.07"
num_50DayMovingAverage="404.85"
num_200DayMovingAverage="381.88"
SharesOutstanding="55956000"
DividendDate="None"
ExDividendDate="None"
symbol="ARGX"
open="545.39"
high="550.76"
low="539.45"
price="548.43"
volume="581081.00"
latest_trading_day="2023-07-21"
previous_close="534.95"
change="13.48"
change_percent="2.5199%"
aroon_positive_momentum_days="61"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Trending Low"
value_analysis="Bearish Trend"
Aroon_change="FALSE"
Aroon_momentum="61"
Volume_recent_avg="279662"
Change_recent_avg="0.59"
Delta_recent_avg="8.61"
Variance_recent_avg="4.3"
Change_ratio_recent_avg="0.13"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="61"
Aroon_momentum_negative="39"
image_negative_thumbnail_id_1="505"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0100.jpeg"
image_negative_thumbnail_id_2="1134"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0167.jpeg"
image_neutral_thumbnail_id_1="539"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0060.jpeg"
image_neutral_thumbnail_id_2="570"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_positive_thumbnail_id_1="649"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0059.jpeg"
image_positive_thumbnail_id_2="681"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0027.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1171"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
